8-K: Dermata Therapeutics Terminates Key License Agreement

Dermata Therapeutics, Inc. has terminated its license agreement with Villani, Inc., signaling a strategic pivot towards over-the-counter skin care treatments and away from its investigational drug pipeline.

Summary

• Dermata Therapeutics, Inc. (DRMA) sent notice on November 17, 2025, to terminate its License Agreement with Villani, Inc., originally dated March 31, 2017.
• The termination was elected without cause, as permitted by the Agreement, and will become effective 90 days after Villani's receipt of the notice.
• This decision aligns with Dermata's recent strategic shift to commercialize over-the-counter (OTC) skin care treatments.
• The Company also withdrew its XYNGARI investigational new drug application (IND) with the U.S. Food and Drug Administration.
• Under the terminated Agreement, Villani had granted Dermata an exclusive, sub-licensable, royalty-bearing license for pharmaceutical products containing sponge for skin conditions.
• Dermata was previously obligated to make future milestone payments to Villani totaling up to $40.5 million and single-digit royalty payments on net sales.
• As a result of the termination, Villani will not receive any further milestone or other payments due after the Termination Date.
• Dermata will cease all development and commercialization obligations related to the Licensed Products, and the licenses granted by Villani will no longer be in effect after the Termination Date.

Sentiment

Score: 5

Explanation: The sentiment is neutral to slightly negative. While the termination eliminates significant future payment obligations, it also signifies the abandonment of a drug development pipeline and a major strategic shift, introducing new uncertainties. The long-term impact depends on the success of the new OTC strategy.

Positives

• Elimination of future milestone payment obligations to Villani, Inc., which could have totaled up to $40.5 million.
• Cessation of single-digit royalty payment obligations on net sales to Villani, Inc.
• Removal of development and commercialization obligations related to the Licensed Products, potentially freeing up resources.

Negatives

• Abandonment of the XYNGARI investigational new drug application, indicating a discontinuation of a previous R&D pipeline asset.
• Loss of an exclusive, sub-licensable, royalty-bearing license for pharmaceutical products containing sponge for skin conditions, which represented a potential future revenue stream from prescription products.

Risks

• The strategic shift to commercialize over-the-counter skin care treatments introduces new market and competitive risks.
• Withdrawal of the XYNGARI IND means the company is abandoning a previously pursued drug development path, potentially writing off prior investments in that program.
• Uncertainty regarding the success and market acceptance of the new OTC skin care treatment strategy.

Future Outlook

Dermata Therapeutics is strategically shifting its focus from investigational new drug development to the commercialization of over-the-counter skin care treatments. This pivot involves discontinuing its XYNGARI IND program and terminating related licensing agreements.

Management Comments

• Gerald T. Proehl, Chief Executive Officer, signed the report on behalf of Dermata Therapeutics, Inc.

Industry Context

This announcement reflects a significant strategic pivot within the pharmaceutical and dermatology sectors. Moving from prescription drug development (IND stage) to over-the-counter (OTC) products typically involves a shift from a high-risk, high-reward, long-development cycle model to a potentially lower-risk, faster-to-market, consumer-focused model. This could indicate challenges in the prescription drug pipeline or a perceived greater opportunity in the OTC market for Dermata Therapeutics.

Comparison to Industry Standards

• NA

Stakeholder Impact

• Shareholders: Will experience a significant strategic shift, moving away from a prescription drug development model to an over-the-counter commercialization model. This could impact future revenue streams, risk profile, and valuation.
• Villani, Inc.: Will lose the potential for up to $40.5 million in milestone payments and single-digit royalty payments on net sales from the terminated license agreement.
• Employees: Potential reallocation of resources and personnel as the company pivots its strategic focus.

Next Steps

• The termination of the License Agreement will become effective 90 days after Villani, Inc.'s receipt of the Company's notice of termination.
• Dermata Therapeutics, Inc. will continue to execute its strategic shift towards commercializing over-the-counter skin care treatments.

Key Dates

Keywords

Dermata Therapeutics, Villani Inc, License Agreement Termination, Strategic Shift, OTC Skin Care, XYNGARI, IND Withdrawal, Pharmaceutical Development, Biotechnology, Dermatology